D
Tempest Therapeutics, Inc. TPST
$6.49 -$0.36-5.26% NASDAQ
Recommendation
Prev Close
$6.49
Volume
28,909
Avg Vol (90D)
69,390
Market Cap
$22.71M
Dividend & Yield
--
52-Week Range
$5.35 - $47.45
P/E (TTM)
--
EPS (TTM)
-$19.84
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
4/28/2025 - Globe Newswire
Tempest Therapeutics (TPST) Gains FDA Orphan Drug Status for TPST-1495 TPST Stock News
4/21/2025 - GuruFocus
Tempest Therapeutics announces FDA granted ODD to TPST-1495
4/21/2025 - The Fly
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
4/21/2025 - Globe Newswire
tempest blows away 80 workforce ride out cash crunch
4/21/2025 - FierceBiotech.com - Biotech
Tempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest Update
4/14/2025 - Ticker Report
Scotiabank Reiterates Sector Perform Rating for Tempest Therapeutics (NASDAQ:TPST)
4/12/2025 - MarketBeat
HC Wainwright Reiterates "Neutral" Rating for Tempest Therapeutics (NASDAQ:TPST)
4/12/2025 - MarketBeat
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success
4/10/2025 - Benzinga
TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up
4/10/2025 - Zacks Investment Research
Tempest Therapeutics (TPST) Downgraded Amid Amezalpat Challenges CHRO Stock News
4/10/2025 - GuruFocus
Tempest Therapeutics downgraded at Scotiabank as amezalpat finds no suitors
4/10/2025 - The Fly
Tempest Therapeutics (TPST) Downgraded to Neutral Amid Strategic Shift TPST Stock News
4/10/2025 - GuruFocus
Scotiabank gets more bearish on Tempest Therapeutics, downgrades shares
4/10/2025 - The Fly
Tempest Therapeutics just downgraded at H.C. Wainwright, here's why
4/10/2025 - The Fly
tempest weathering stormy capital market calls partners liver cancer drug
4/10/2025 - FierceBiotech.com - Biotech
Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger
4/10/2025 - Stocktwits News Feed
Tempest Therapeutics Terminates Loan Agreement with Oxford
4/9/2025 - TipRanks Financial Blog
Tempest Therapeutics (TPST) Explores Strategic Alternatives Amid Capital Constraints TPST ...
4/9/2025 - GuruFocus
Tempest Therapeutics to explore strategic alternatives
4/9/2025 - The Fly
Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value
4/9/2025 - Globe Newswire
Tempest Therapeutics, Inc. (NASDAQ:TPST) Sees Large Decline in Short Interest
4/1/2025 - Ticker Report
Tempest Therapeutics treatment of FAP granted FDA orphan designation
3/31/2025 - TipRanks Financial Blog
Tempest Therapeutics treatment of FAP granted FDA orphan designation
3/31/2025 - The Fly
Scotiabank Reaffirms Their Buy Rating on Tempest Therapeutics (TPST)
3/28/2025 - TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$41.64M
EBIT (TTM)
-$42.03M
Net Income (TTM)
-$41.84M
Balance Sheet
Total Assets (Q)
$41.49M
Total Debt (Q)
$15.37M
Total Liabilities (Q)
$22.36M
Book Value Per Share (Q)
$5.65
Cash Flow
Cash from Operations (TTM)
-$33.03M
Cash from Investing (TTM)
-$435.00K
Cash from Financing (TTM)
$24.50M
Net Change in Cash (TTM)
-$8.96M
Filings
Filing Date
Thursday, March 27, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
2.61
7-Day Total Return
-5.26%
30-Day Total Return
-35.34%
60-Day Total Return
-46.45%
90-Day Total Return
-40.43%
Year to Date Total Return
-41.84%
1-Year Total Return
-84.64%
2-Year Total Return
-75.77%
3-Year Total Return
-83.13%
5-Year Total Return
--
52-week Low
Apr 07, 2025 - $5.35
52-week High
May 30, 2024 - $47.45
Valuation
Market Cap
$22.71M - Nano Cap
Enterprise Value
$7.80M
Price/Sales (TTM)
--
Price/Book (Q)
1.15
Dividends and Shares
Shares Outstanding
3.15M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.tempesttx.com
Phone Number
415 798 8589
Address
2000 Sierra Point Parkway
Brisbane, CA 94005
Country
United States
Year Founded
2011
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various cancers. The... more
NASDAQ 05/09/2025 4:00PM Eastern Quotes delayed